businesspress24.com - Fluoroquinolone Antibiotics: Patients With Myasthenia Gravis May Risk Increased Muscle Weakness
 

Fluoroquinolone Antibiotics: Patients With Myasthenia Gravis May Risk Increased Muscle Weakness

ID: 1054115

(firmenpresse) - OTTAWA, ONTARIO -- (Marketwire) -- 11/07/11 -- Patients with a rare condition known as myasthenia gravis who take a fluoroquinolone antibiotic may risk a worsening of their symptoms, including muscle weakness or breathing problems. The risk of this happening is considered rare, but serious. Use of fluoroquinolone antibiotics should be avoided in patients with a known history of myasthenia gravis.

Myasthenia gravis is a rare, chronic (long-lasting and recurring) disease that causes progressive muscle weakness. Muscles affected by this condition include eye and face muscles, neck and throat muscles, and limb muscles. Activity makes the muscle weakness worse, and symptoms generally improve with rest.

Fluoroquinolone antibiotics are a class of prescription drugs used to treat certain types of bacterial infections in adults, such as respiratory tract infections, skin infections and urinary tract infections. (See below for a list of fluoroquinolone drugs in Canada).

Health Canada has notified the Canadian manufacturers of fluoroquinolone antibiotics to update the labelling to include a warning on this risk.

There are alternative antibiotics available in Canada. Patients with myasthenia gravis should:

How to report side effects to health products

To report suspected adverse reaction to these or other health products, please contact Health Canada's Canada Vigilance Program toll-free at 1-866-234-2345, or complete a () and send to us using one of these methods:

Fax: 1-866-678-6789

Internet:

Mail ( ()):

Fluoroquinolone drugs currently marketed in Canada

Fluoroquinolone antibiotics are available in multiple formulations. The risk to myasthenia gravis patients appears to apply to formulations taken by mouth (liquids and tablets/extended release tablets) or that are injected intravenously (into a vein). Based on available data, the risk does not appear to apply to ear or eye drops.





Below is a list of brand names of fluoroquinolone antibiotics, their generic equivalent and the active ingredient. There are many fluoroquinolone antibiotics currently sold in Canada; for simplicity, the table provides the drug names, but not the variations in strengths, formulations or routes of administration.

Egalement disponible en francais



Contacts:
Media Inquiries:
Health Canada
613-957-2983

Public Inquiries:
613-957-2991
1-866-225-0709


Themen in dieser Pressemitteilung:


Unternehmensinformation / Kurzprofil:



Leseranfragen:



PresseKontakt / Agentur:



drucken  als PDF  an Freund senden  NAVCANatm Flight Data Technology Extends to the Dutch Caribbean
Minister Ritz Announces Crop Logistics Working Group
Bereitgestellt von Benutzer: MARKET WIRE
Datum: 07.11.2011 - 09:52 Uhr
Sprache: Deutsch
News-ID 1054115
Anzahl Zeichen: 0

contact information:
Contact person:
Town:

OTTAWA, ONTARIO


Phone:

Kategorie:

Government & Administration


Anmerkungen:


Diese Pressemitteilung wurde bisher 89 mal aufgerufen.


Die Pressemitteilung mit dem Titel:
"Fluoroquinolone Antibiotics: Patients With Myasthenia Gravis May Risk Increased Muscle Weakness
"
steht unter der journalistisch-redaktionellen Verantwortung von

Health Canada (Nachricht senden)

Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).


Alle Meldungen von Health Canada



 

Who is online

All members: 10 568
Register today: 0
Register yesterday: 0
Members online: 0
Guests online: 103


Don't have an account yet? You can create one. As registered user you have some advantages like theme manager, comments configuration and post comments with your name.